Versant Ventures VI GP-GP, LLC's Net Worth

$206 Million

Who is Versant Ventures VI GP-GP, LLC?

Versant Ventures VI GP-GP, LLC has an estimated net worth of $206 Million. This is based on reported shares across multiple companies, which include Monte Rosa Therapeutics, Inc., Oyster Point Pharma, Inc., Pandion Therapeutics, Inc., Passage BIO, Inc., Graphite Bio, Inc., Repare Therapeutics Inc., Century Therapeutics, Inc., Tempest Therapeutics, Inc., and Akero Therapeutics, Inc..

SEC CIK

Versant Ventures VI GP-GP, LLC's CIK is 0001777652

Past Insider Trading and Trends

2021 was Versant Ventures VI GP-GP, LLC's most active year for acquiring shares with 42 total transactions. Versant Ventures VI GP-GP, LLC's most active month to acquire stocks was the month of May. 2021 was Versant Ventures VI GP-GP, LLC's most active year for disposing of shares, totalling 67 transactions. Versant Ventures VI GP-GP, LLC's most active month to dispose stocks was the month of December. 2019 saw Versant Ventures VI GP-GP, LLC paying a total of $9,440,000.00 for 5,257,825 shares, this is the most they've acquired in one year. In 2022 Versant Ventures VI GP-GP, LLC cashed out on 2,948,028 shares for a total of $16,355,385.00, their largest year based on trade value.